Slide 1RandomForest as a Variable Selection Tool for Biomarker Data Katja Remlinger GlaxoSmithKline, RTP, NA ICSA Applied Statistics Symposium June 6 th, 2007 Slide 2 Outline…

Slide 1 Clinical Review Process: An FDA Perspective Karen Midthun, M.D. Deputy Director of Medicine Center for Biologics Evaluation and Research FDA April 15, 2005 Slide…

Slide 1 Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study Design…

Slide 1 Application of Toxicology Databases in Drug Development (Estimating potential toxicity) Joseph F. Contrera, Ph.D. Director, Regulatory Research and Analysis FDA Center…

DPC 083 ATAC Meeting Seattle February 24, 2002 Nancy Ruiz, MD DPC 083-201 A Phase II Double-Blind (DB) Comparison of 3 Once Daily Doses of the NNRTI DPC 083 vs 600 mg Efavirenz…

DPC 083 ATAC Meeting Seattle February 24, 2002 Nancy Ruiz, MD DPC 083-201 A Phase II Double-Blind (DB) Comparison of 3 Once Daily Doses of the NNRTI DPC 083 vs 600 mg Efavirenz…

* Observations from the Antiviral Information Management System (AIMS) Database Jeffry Florian, Ph.D. CDER/OTS/OCP Division of Pharmacometrics, Reviewer The opinions and…

Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti-Infective Drug Advisory Committee Hugo E. Gallo-Torres, M.D.,…

Receptor pharmacology or animal models for dose selection in humans? Bart Laurijssens Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, UK Satellite Meeting…

Overview of Targeted Therapies for Esophageal and Gastric Cancers Johanna Bendell, MD Director, GI Oncology Research Associate Director, Drug Development Unit Sarah Cannon…